Azelaic Acid Side Effects: Rare but Serious Adverse Events Women Should Know

What Counts as a "Rare but Serious" Adverse Event With Azelaic Acid?

Most women using azelaic acid 15-20% experience only local skin irritation. Rare adverse events are those occurring in fewer than 1 in 1,000 users, but their severity means they require prompt medical attention.

The FDA-approved prescribing information for Finacea (azelaic acid) 15% gel and Azelex (azelaic acid) 20% cream lists the following serious adverse events identified from clinical trials and post-market surveillance:

• Rare allergic reactions including angioedema (swelling of the face, lips, or throat)
• Bronchospasm and worsening of pre-existing asthma
• Severe skin reactions beyond expected irritation, including exfoliative dermatitis
• Eye irritation with potential corneal involvement if the gel contacts ocular surfaces

These events are rare. They are not hypothetical. Any woman starting azelaic acid who has asthma, atopy, or a history of contact hypersensitivity should discuss the risk profile with her clinician before the first application.

Why "Rare" Still Matters at a Population Level

About 16 million Americans have rosacea, and women account for roughly three-quarters of diagnosed cases. Azelaic acid is a first-line topical treatment for rosacea according to the American Academy of Dermatology guidelines. When a drug is used by millions, even a 0.1% serious adverse event rate translates to thousands of affected individuals. Scale matters.

The FAERS Signal

The FDA Adverse Event Reporting System (FAERS) contains post-market reports of bronchospasm and hypersensitivity following topical azelaic acid use. Because FAERS is a passive surveillance database, it cannot establish causation or true incidence rates. What it can do is flag signals that warrant clinical awareness. Bronchospasm appears repeatedly in the serious-event category for this drug, making it the single most clinically consequential rare risk to communicate to patients.

Bronchospasm and Respiratory Reactions: The Risk Women With Asthma Must Understand

Bronchospasm is the most serious rare adverse event associated with azelaic acid, and it disproportionately matters for women because asthma affects women at higher rates than men after puberty, with prevalence rising again during perimenopause due to estrogen fluctuations.

Mechanism

Azelaic acid is a dicarboxylic acid. At concentrations of 15-20%, it can act as a mild irritant to mucous membranes, and in sensitive individuals the vehicle excipients (propylene glycol, polysorbate 80 in some formulations) may also provoke airway reactivity. The mechanism of bronchospasm is not fully characterized in the published literature. The Finacea prescribing label explicitly warns that the drug should be used with caution in patients with asthma.

Which Women Are at Highest Risk?

Women with any of the following should be counseled specifically before starting azelaic acid:

• Diagnosed asthma or reactive airway disease
• Atopic triad (asthma plus allergic rhinitis plus eczema)
• A history of aspirin-exacerbated respiratory disease
• Perimenopausal women with new-onset airway hyperreactivity, which research from the Nurses Health Study II links to hormonal fluctuation

What to Do If Respiratory Symptoms Develop

Stop the medication immediately. Bronchospasm after topical application can develop within minutes to hours of exposure. Call emergency services if breathing is significantly compromised. Inform your clinician and file a MedWatch report through the FDA's voluntary reporting portal.

Hypersensitivity and Allergic Reactions: Contact Dermatitis vs. True Allergy

Distinguishing between irritant contact dermatitis (very common, expected, usually self-limiting) and true allergic contact dermatitis or systemic hypersensitivity (rare, potentially serious) is essential.

Irritant Contact Dermatitis (Common, Not Serious)

Up to 29% of patients in the key Finacea phase III trials reported burning, stinging, or tingling at the application site. This is an expected irritant response, not an allergic reaction. It typically peaks in the first two weeks and diminishes as the skin accommodates.

Managing expected irritation:

• Apply a fragrance-free moisturizer 10-15 minutes before applying azelaic acid
• Start with once-daily application and increase to twice daily only after two weeks of tolerance
• Avoid concurrent use of other acids (glycolic acid, salicylic acid) during the adjustment period

Allergic Contact Dermatitis (Rare, Potentially Serious)

True allergic contact dermatitis to azelaic acid itself is uncommon given that azelaic acid occurs naturally in wheat, rye, and barley. Allergy to excipients, particularly propylene glycol and benzoic acid in some formulations, is a more common driver of true allergic reactions. Patch testing studies have confirmed propylene glycol as a sensitizer in a subset of patients.

Signs that suggest allergic rather than irritant contact dermatitis:

• Rash spreading beyond the application zone
• Persistent or worsening redness after the first four weeks rather than improving
• Oozing, crusting, or vesicle formation
• Systemic symptoms such as hives, facial swelling, or difficulty breathing

Angioedema: A Rare Emergency

Angioedema involving the lips, tongue, or throat is documented in post-market reports for topical azelaic acid. It is rare. It is an emergency. Women with a personal or family history of hereditary angioedema, or those taking ACE inhibitors for conditions like hypertension or diabetic nephropathy, should discuss the theoretical additive risk with their prescribing clinician.

Serious Skin Reactions Beyond Expected Irritation

Exfoliative Dermatitis

Exfoliative dermatitis, characterized by widespread skin redness, scaling, and shedding, has been reported with azelaic acid use in case series and post-market surveillance. It is distinct from normal peeling. The FDA label for Azelex 20% cream notes rare reports of skin reactions requiring discontinuation.

Women using azelaic acid on large surface areas for PCOS-related widespread acne may face a proportionally higher exposure burden. There is no published trial data on systemic absorption at body sites other than the face, and this constitutes a known evidence gap.

Hypopigmentation in Darker Skin Tones

Azelaic acid inhibits tyrosinase, the enzyme central to melanin synthesis. This is the mechanism behind its use for melasma and post-inflammatory hyperpigmentation. However, in darker skin tones, prolonged use or high-concentration application can cause unintended hypopigmentation, patchy lightening that may not fully reverse.

A review in the Journal of the American Academy of Dermatology describes azelaic acid-induced hypopigmentation primarily in individuals with Fitzpatrick skin types IV-VI. Women of South Asian, Black, Latina, or Middle Eastern backgrounds using azelaic acid for hormonal acne or melasma related to PCOS or pregnancy should monitor for patchy lightening and report it promptly. This is not listed as a "serious" adverse event in the prescribing information, but it carries cosmetic and psychological significance that the evidence base largely overlooks, and it represents a documented disparity in how the drug's risk profile has been communicated.

Eye Irritation and Corneal Risk

The Finacea prescribing information warns specifically against contact with the eyes. If azelaic acid gel enters the eye, it can cause significant irritation and, in animal models, has demonstrated corneal effects. Human case reports of chemical conjunctivitis following accidental ocular exposure exist in the literature. Women applying the gel near the periorbital area for rosacea flushing patterns that extend to the lower eyelid margin must take particular care.

Rinse thoroughly with warm water if eye contact occurs. If irritation persists beyond 30 minutes, seek ophthalmologic evaluation.

Women-Specific Adverse Event Considerations by Life Stage

The risk profile of azelaic acid is not uniform across a woman's life. Hormonal status, skin physiology, and co-existing conditions shift both likelihood and clinical impact of adverse events.

Reproductive Years and PCOS

Azelaic acid is frequently used off-label for hormonal acne in women with polycystic ovary syndrome. PCOS affects between 8-13% of reproductive-age women globally. Women with PCOS often have thicker sebaceous follicles and increased skin sensitivity due to androgen excess and insulin resistance.

No dedicated clinical trials have evaluated azelaic acid safety specifically in women with PCOS. The evidence is extrapolated from general acne and rosacea trials, the vast majority of which included participants without endocrine comorbidities. This is a real evidence gap. Women with PCOS may also be using concurrent medications (spironolactone, metformin, oral contraceptives) whose interaction with topical azelaic acid has not been systematically studied.

Trying to Conceive

Women trying to conceive can generally continue azelaic acid. Systemic absorption from topical application is low. After application of 15% gel to the face, pharmacokinetic studies show that plasma levels remain within the endogenous range (40-80 ng/mL), meaning azelaic acid at therapeutic topical doses does not meaningfully raise circulating levels above what the body already produces from dietary sources. There is no published evidence of impaired fertility or embryotoxicity at these systemic exposures.

Pregnancy

Azelaic acid is classified as FDA Pregnancy Category B. Animal reproduction studies have not shown fetal harm at doses relevant to topical use. Human data are limited to observational reports and small case series rather than prospective controlled trials.

ACOG and dermatology consensus guidance generally considers azelaic acid one of the safer topical options for managing acne or melasma during pregnancy, particularly in the second and third trimester when facial pigmentation changes (melasma gravidarum) peak.

Key points for pregnant women:

• Avoid application to the nipple or areola area even during pregnancy, to reduce potential ingestion risk for the newborn after delivery
• Do not apply to large body surface areas where occlusion (clothing, bandaging) may increase absorption
• If rosacea flares during pregnancy (a documented association given vascular changes), azelaic acid is preferred over topical metronidazole or ivermectin, for which safety data in pregnancy are even more limited

Postpartum and Lactation

Azelaic acid is considered compatible with breastfeeding. Because systemic absorption is minimal and azelaic acid is a naturally occurring fatty acid present in human breast milk, the risk of infant exposure via milk is considered negligible. Do not apply directly to the nipple or areola before nursing. Wash hands thoroughly after each application.

Postpartum women experiencing acne related to hormonal shifts (the dramatic drop in estrogen and progesterone after delivery) may find azelaic acid particularly useful precisely because it does not require stopping breastfeeding. This is a practical clinical advantage over alternatives like oral retinoids (contraindicated during lactation) or oral tetracyclines (used with caution).

Perimenopause

Rosacea prevalence increases markedly in women in their 40s and 50s, mirroring the timing of perimenopause. The National Rosacea Society estimates that menopausal flushing and rosacea flushing are frequently confused and co-occur. Estrogen decline alters skin barrier function, reducing ceramide content and increasing transepidermal water loss, which means perimenopausal skin is more susceptible to the irritant effects of azelaic acid.

Perimenopausal women using azelaic acid 15% for rosacea should expect a longer adjustment period (up to six weeks rather than two) before irritation settles. Women also using topical estradiol for genitourinary syndrome of menopause (GSM) on facial mucosa or around the hairline should keep azelaic acid and hormone gels separated by at least two hours to avoid any theoretical interaction with barrier integrity.

The evidence gap here is substantial. No clinical trials have specifically enrolled perimenopausal women to evaluate azelaic acid tolerability or efficacy against a younger cohort. Clinicians and patients are extrapolating from mixed-age rosacea trial populations.

Post-Menopause

Post-menopausal skin has lower sebum production, thinner dermis, and reduced collagen density. These changes can increase sensitivity to topical acids. Women who developed new rosacea or inflammatory acne after menopause should start at once-daily application and reassess at four weeks before escalating to twice daily. There is no upper age limit for using azelaic acid, but the comfort-versus-benefit calculation shifts as skin becomes more fragile.

Drug Interactions and Co-Medication Considerations for Women

Azelaic acid is not metabolized by cytochrome P450 enzymes. Systemic drug-drug interactions are unlikely at topical therapeutic doses. The clinically relevant co-medication questions are topical, not systemic.

• Concurrent use of tretinoin: Both agents cause skin irritation. Using them together increases the likelihood of significant irritant contact dermatitis. If combining, apply at different times of day (tretinoin at night, azelaic acid in the morning) and introduce one at a time.
• Benzoyl peroxide: Can oxidize azelaic acid and reduce its efficacy. The combination is used clinically but the evidence base for combination is weak and comes from small open-label studies rather than head-to-head randomized controlled trials.
• Topical corticosteroids: Women prescribed low-potency topical steroids for perioral dermatitis (a condition that flares on hormonal contraceptives) and concurrently using azelaic acid should be aware that steroid-induced skin thinning may increase azelaic acid penetration and irritant potential.
• Spironolactone users: No documented pharmacokinetic interaction. Both are used for hormonal acne in PCOS; the combination is common in clinical practice, with azelaic acid addressing surface inflammation while spironolactone addresses androgen-driven sebum production.

Who This Is Right For, and Who Should Proceed With Caution

Women Who Are Good Candidates

• Pregnant or breastfeeding women with acne or rosacea who need a topical option with a favorable safety profile
• Women with PCOS seeking a topical agent for hormonal acne without systemic exposure
• Perimenopausal women with new or worsening rosacea
• Women with darker skin tones managing post-inflammatory hyperpigmentation, with close monitoring for unintended hypopigmentation
• Women who cannot tolerate retinoids (due to pregnancy, skin sensitivity, or cost)

Women Who Should Proceed With Caution or Discuss First

• Women with diagnosed asthma or reactive airway disease
• Women with atopic dermatitis covering large body surface areas, where barrier disruption may increase local or systemic irritant effects
• Women with a history of hereditary angioedema
• Women with Fitzpatrick skin types IV-VI using high concentrations over extended periods, due to hypopigmentation risk
• Women applying azelaic acid near the orbital rim for periorbital rosacea, given ocular exposure risk

Recognizing and Reporting Serious Adverse Events

Serious adverse events from azelaic acid are rare enough that many clinicians have never seen one. That means women are often the first to identify a problem.

The FDA's MedWatch program accepts voluntary reports from patients and healthcare providers. Filing a report when you experience an unexpected or serious reaction contributes directly to post-market safety surveillance and helps generate the signal data that leads to label updates.

Warning signs that require stopping the medication and contacting a clinician promptly:

• Difficulty breathing or wheezing after application
• Swelling of the face, lips, tongue, or throat
• Severe worsening of skin with redness extending well beyond the treated area
• Rash on areas of skin not treated with the product
• Significant eye pain or prolonged visual disturbance after accidental ocular contact

Any woman who experiences these symptoms should treat them as urgent and not wait for a routine appointment.

"The most important thing women with asthma need to understand is that 'topical' does not automatically mean 'safe for your airways,'" says Elena Vasquez, MD, WomanRx medical reviewer and board-certified dermatologist-trained OB-GYN. "The evidence for bronchospasm with azelaic acid is not large, but it is real, and women with reactive airway disease deserve explicit counseling before they start, not after they call with a wheezing episode."

Evidence Gaps Women and Clinicians Should Acknowledge

The clinical trial record for azelaic acid has significant gaps specific to female biology:

• No randomized controlled trial has enrolled exclusively or primarily women with PCOS to evaluate safety and efficacy of azelaic acid for hormonal acne
• Pharmacokinetic data in pregnancy come from one small study published in 1994 involving a limited sample. Plasma level measurements in pregnant women are extrapolated from non-pregnant adults
• Perimenopausal and post-menopausal women were not analyzed as a separate subgroup in the key Finacea phase III trials, per the FDA clinical review documents
• Hypopigmentation risk in women with Fitzpatrick skin types IV-VI is documented in case reports but has not been the subject of a prospective study

Acknowledging these gaps is not a reason to avoid the drug. It is a reason to monitor more carefully, document outcomes, and report unexpected events through MedWatch so the evidence base can grow.